JonesTrading analyst Sean Kim PhD reiterated a Buy rating on aTyr Pharma (LIFE – Research Report) today and set a price target of $15.00. The company’s shares opened today at $2.75.
According to TipRanks, Kim PhD is a 2-star analyst with an average return of -0.4% and a 33.33% success rate. Kim PhD covers the Healthcare sector, focusing on stocks such as Ocuphire Pharma, Concert Pharma, and CymaBay Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for aTyr Pharma with a $18.50 average price target.
See today’s best-performing stocks on TipRanks >>
LIFE market cap is currently $79.86M and has a P/E ratio of -1.73.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More on LIFE:
- aTyr Pharma receives FDA Fast Track designation for efzofitimod
- aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
- aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
